EP1734997
Natalísúmab til notkunar við meðhöndlun á sjúkdómum sem þarfnast sterameðhöndlunar
Status:
EP Einkaleyfi ógilt eftir andmæliEP appl. date:
30.3.2005EP published:
2.9.2015EP application number:
05768245.2
EP translation filed:
2.12.2015Grant published:
15.1.2016EPO information:
European Patent Register
Max expiry date:
29.3.2025Expiry date:
29.3.2025
Title:
NATALIZUMAB FOR USE IN TREATING DISEASES NEEDING STEROID TREATMENT
Timeline
Today
30.3.2005EP application
2.9.2015EP Publication
2.12.2015Translation submitted
15.1.2016Registration published
29.3.2025Expires
Owner
Name:
Biogen Idec MA Inc.Address:
14 Cambridge Center, 02142, Cambridge, MA, US
Inventor
Name:
LIEBERBURG, IvanAddress:
Berkeley, California, US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
558120 PDate:
1.4.2004Country:
US
Classification
Categories:
A61K 39/395, A61P 1/00, A61P 11/06, A61P 37/00
Annual fees
Number
Paid
Expires
Payer
Number: 12
Paid: 1.3.2016
Expires: 29.3.2017
Payer: Sigurjónsson & Thor ehf.
Number: 13
Paid: 2.3.2017
Expires: 29.3.2018
Payer: Sigurjónsson & Thor ehf.
Number: 14
Paid: 26.3.2018
Expires: 29.3.2019
Payer: Árnason Faktor
Number: 15
Paid: 27.3.2019
Expires: 29.3.2020
Payer: Tego ehf.
Number: 16
Paid: 18.2.2020
Expires: 29.3.2021
Payer: Árnason Faktor ehf.
Number: 17
Paid: 8.2.2021
Expires: 29.3.2022
Payer: Árnason Faktor ehf.
Number: 18
Paid: 8.2.2022
Expires: 29.3.2023
Payer: Árnason Faktor ehf.
Number: 19
Paid: 22.2.2023
Expires: 29.3.2024
Payer: Árnason Faktor ehf.
Number: 20
Paid: 6.3.2024
Expires: 29.3.2025
Payer: Árnason Faktor ehf.